Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Prior treatment

• Presence of an implant (excluding intraocular lens), opacification of the refractive medium or miosis that affects fundus examination;

Other illness

• Have any other cause of CNV (such as pathological myopia, etc.) in the study eye; or non-nAMD disease in the study eye judged by the investigator that could impact macular examination or affect central vision (such as diabetic retinopathy, central retinal vein occlusion, etc.);
• Any condition preventing visual acuity improvement in the study eye, e.g. fovea scar, fibrosis or atrophy;
• Have a subretinal hemorrhage that is either 50% or more of the total lesion area, or blood is greater than 1.0 mm2 under the fovea in the study eye at screening;
• Have any vitreous hemorrhage or history of vitreous hemorrhage in the study eye;
• Have a history of or presence of retinal detachment or choroidal detachment in the study eye.

• Are willing and able to sign the informed consent form (ICF);
• Female and male aged 50 to 85 years (inclusive) with nAMD;
• Have previously received anti-VEGF treatment for nAMD, with documented response to anti-VEGF therapy and a minimum of 2 anti-VEGF IVT injections in the study eye in the 6 months prior to screening;
• Have a ETDRS BCVA letter score of 83 to 19 (approximately 20/25 to 20/400 Snellen equivalent) in the study eye at Screening;
• Have a ETDRS BCVA letter score of ≥19 in the fellow eye at Screening;
• Females must be at least 1 year postmenopausal.